Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.

Authors:
Sakamoto Y; Ishida T; Masaki A; Murase T; Takeshita M and 12 more

Journal:
Br J Haematol

Publication Year: 2021

DOI:
10.1111/bjh.17749

PMCID:
PMC9291095

PMID:
34405395

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Haematol

Abbreviation: Br J Haematol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accumulation of foamy macrophages in the bone marrow following chronic intravenous drug use.
Kyla Y; Penelope K; Kerry BM and 1 more (2022) - Transparency Score: 1/6
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with elt…
Al-Samkari H; Jiang D; Gernsheimer T and 5 more (2022) - Transparency Score: 3/6
Antithrombin-III mitigates thrombin-mediated endothelial cell contraction and sickle red blood cell…
Wulftange WJ; Kucukal E; Man Y and 10 more (2022) - Transparency Score: 4/6
A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute l…
Andersson NG; Rathe M; Mølle I and 12 more (2022) - Transparency Score: 3/6
BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
Branford S. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"details are available in data s1 ?; details are available in data s1 .; details are available in data s1 .; details are available in data s1 ?; details are available in data s1 ? the start date for assessing overall survival (os) was defined as the day when the tumour sample was obtained.; details are available in data s1 .; data s1 ."

Code Sharing
Evidence found in paper:

"Conflicts of interest HI received research funding from Kyowa Kirin Co., Ltd. SK received research funding from Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd., and received honoraria from Chugai Pharmaceutical Co., Ltd. and Kyowa Kirin Co., Ltd. NN received honoraria from Novartis, Takeda pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Celgene, Otsuka Pharmatceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., and Asahi Kasei Pharma Co., Ltd., and received consulting fee from JIMRO. KY received honoraria from AbbVie, Celgene, Daiichi Sankyo Co., Ltd., Eisai, Eli Lilly Japan, Janssen Pharmaceuticals, Kaken Pharmaceutical, Kyowa Kirin Co., Ltd., Maruho, Minophagen Pharmaceutical, Novartis, Sanofi, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Japan. SI received honoraria from Janssen, Celgene, Ono, Takeda, Sanofi, and Daiichi Sankyo Co., Ltd., and received research funding from Sanofi, Chugai, Ono, Takeda, Kyowa Kirin Co., Ltd., Celgene, Janssen, Bristol‐Myers Squibb, Abbie, and Glaxo‐Smith‐Klein. AU received honoraria from Kyowa Kirin Co., Ltd, Daiichi Sankyo Co., Ltd., Bristol‐Myers and Celgene, and received consulting fees from HUYA Japan, JIMRO, Meiji Seika Pharma Co., Ltd. and Otsuka Medical Devices Co., Ltd. RU received research funding from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. The other authors have no conflicts of interest to disclose."

Evidence found in paper:

"Funding information This work was supported by grants‐in‐aid for Early‐Career Scientists (20K16177 to YS), and the Nitto Foundation (YS), Grants‐in‐aid from the Japan Agency for Medical Research and Development (No. 20ae0101074h0001 and 21ae0101074h0001 to RU, and No. 20cm0106301h0005 and 21cm0106301h0005 to TI)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025